Expression and prognostic significance of human peroxiredoxin isoforms in endometrial cancer

Oncology Letters

Volumn 3, Issue 6, 2012, Pages 1275-1279

  Han, Seulhee ^a   Shen, Haiying ^a   Jung, Minhyung ^b   Hahn, Bum Soo ^b,c   Jin, Byung Kwan ^b   Kang, Insug ^a   Ha, Joohun ^a   Choe, Wonchae ^a  

^a Biomedical Science Institute   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c National Academy of Agricultural Science   (South Korea)

Author keywords

Endometrial cancer; Peroxiredoxin; Reactive oxidative species

Indexed keywords

ISOENZYME; PEROXIREDOXIN; PEROXIREDOXIN 1; PEROXIREDOXIN 2; PEROXIREDOXIN 3; PEROXIREDOXIN 4; PEROXIREDOXIN 5; PEROXIREDOXIN 6;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; ENDOMETRIUM; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; SURVIVAL RATE; UPREGULATION;

EID: 84859447747     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.648     Document Type: Article

References (16)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin 57: 43-66, 2007.
2. Chae HZ, Kim IH, Kim K and Rhee SG: Cloning, sequencing, and mutation of thiol-specific antioxidant gene of Saccharomyces cerevisiae. J Biol Chem 268: 16815-16821, 1993.
3. Chae HZ, Kim IH, Kim K and Rhee SG: Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc Natl Acad Sci USA 91: 7017-7021, 1994.
4. Chae HZ, Uhm TB and Rhee SG: Dimerization of thiol-specific antioxidant and the essential role of cysteine 47. Proc Natl Acad Sci USA 91: 7022-7026, 1994.
5. Hofmann B, Hecht HJ and Flohe L: Peroxiredoxins. Biol Chem 383: 347-364, 2002.
6. Rhee SG, Kang SW, Netto LE, Seo MS and Stadtman ER: A family of novel peroxidases, peroxiredoxins. Biofactors 10: 207-209, 1999.
7. Wood ZA, Schröder E, Robin HJ and Poole LB: Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 28: 32-40, 2003.
8. Chang JW, Lee SH, Jeong JY, Chae HZ, Kim YC, Park ZY and Yoo YJ: Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small cell lung cancer. FEBS Lett 579: 2873-2877, 2005.
9. Karihtala P, Mäntyniemi A, Kang SW, Kinnula VL and Soini Y: Peroxiredoxins in breast carcinoma. Clin Cancer Res 9: 3418-3424, 2003.
10. Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA and Chae HZ: Overexpression of peroxiredoxin in human breast cancer. Anticancer Res 21: 2085-2090, 2001.
11. Wu XY, Fu ZX and Wang XH: Peroxiredoxins in colorectal neoplasms. Histol Histopathol 25: 1297-1303, 2010.
12. Basu A, Banerjee H, Rojas H, Martinez SR, Roy S, Jia Z, Lilly MB, De León M and Casiano CA: Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. Prostate 71: 755-765, 2010.
13. Choi JH, Kim TN, Kim S, Baek SH, Kim JH, Lee SR and Kim JR: Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res 22: 3331-3335, 2002.
14. Kim KY, Yu MR, Han SH, Oh IK, Choi YJ, Kim SS, Yoon KS, Jung MH and Choe W: Expression of human peroxiredoxin isoforms in response to cervical carcinogenesis. Oncol Rep 21: 1391-1396, 2009.
15. Zhou Y, Kok KH, Chun AC, Wong CM, Wu HW, Lin MC, Fung PC, Kung H and Jin DY: Mouse peroxiredoxin V is a thioredoxin peroxidase that inhibits p53-induced apoptosis. Biochem Biophys Res Commun 268: 921-927, 2000.
16. Abbas K, Breton J, Picot CR, Quesniaux V, Bouton C and Drapier JC: Signaling events leading to peroxiredoxin 5 up-regulation in immunostimulated macrophages. Free Radic Biol Med 47: 794-802, 2009.